Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment.

With improvements to the stent graft delivery system enabling a 1 Fr profile reduction on the majority of sizes, the device now offers the most 6 Fr compatible configurations among balloon expandable stent grafts.

A new microscopy technique that enables high-resolution imaging could one day help doctors diagnose and treat brain tumors.

Magstim announced today that it received FDA clearance for its Horizon 3.0 transcranial magnetic stimulation (TMS) system with StimGuide Pro.

A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of the ReCET™ System in Adult Patients with Type 2 Diabetes

Using a DNA-based scaffold carrying viral proteins, researchers created a vaccine that provokes a strong antibody response against SARS-CoV-2.

Tyber Medical Broadens Its Vast Plating Portfolio with FDA Approval of Additional Screw and Plate Options, and Indications for Mini-Frag System

CARLSBAD, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of its United States Patent No: 11,832,853 entitled “Hybrid Radiolucent Surgical Operating Tube”.